RE: <<ts time to celebrate; I think I'll be drinking Coke rather than Pepsi tonight! >> Good idea ...let me BUY!
In regards to CYPB's drug for RA, I bought in @ 3 5/8 a while ago anticipating a nice move! In regards to RA drugs out there now and undergoing phase III trials, I'm not in a position to judge who will blow away whom, etc., but the antiTNF Avakine approach is supposedly viable. Further, I would expect various analysts to speak out on any Avakine/RA potential issues...for now, however, I believe CNTO has a foot in the door and has a good probability of getting some of the RA pie, which is also good for RA patients.
Yes, this stock is event driven and many will sell out on a run up. On the other hand, Mr. Hecht's $70 target in 12 months may have some merit. Let's hope so!
Perhaps we also need to get more input from the medical arena as to the Reopro price competition; i.e., effectiveness vs cost of various drugs for given condition(s). I'll call CNTO see what kind of response I get!
FNS
|
